Data Analysis System identifies lead compounds.
Share:
Press Release Summary:
Integrating IDBS' MathIQ software with Vitra's CellCard(TM) System, package provides curve fitting and expansive statistical capabilities validated by NIST and UK's National Physical Laboratory. CellCard provides biological insight into effects of lead compounds upon multiple targets or tissue types by enabling simultaneous analysis of selectivity and activity in single well. MathIQ complements CellPlex analysis software by enabling researchers to graph and customize data results.
Original Press Release:
Vitra Bioscience and IDBS Sign Licensing Agreement Combining Tools to Accelerate the Identification of Lead Compounds
MOUNTAIN VIEW, Calif. and GUILDFORD, England, Jan. 31 - Vitra Bioscience, an innovator of technologies for improved analysis and characterization of new lead compounds in drug discovery programs, and IDBS, a leading provider of software for the integrated capture, management and use of chemical and biological data in drug discovery, today announced a licensing agreement merging IDBS' MathIQ software with Vitra's CellCard(TM) System. The new combined solution is a fully integrated data analysis package. It provides scientists with ready-to-use curve fitting and expansive statistical capabilities -- validated by the National Institute of Standards and Technology and the United Kingdom's National Physical Laboratory -- to analyze data directly on the CellCard System, alleviating the need for specialist IT support.
"We are very pleased to integrate our platform with IDBS' MathIQ data analysis capabilities," commented Andrew P. Whiteley, President and CEO of Vitra Bioscience. "There is a clear need for a suite of data analysis tools for drug discovery researchers to utilize with the comprehensive data generated by our CellCard System and CellPlex Assays. In addition to the integration of a superior range of curve fitting and statistical models, this combined solution includes an advanced formula editor that allows drug discovery researchers to input institutional-specific or user-defined equations for faster interpretation of data, more efficient decision making and, ultimately, in selecting the best new drug compound."
"Using validated data analysis tools during the discovery process is paramount since stored data and results are heavily relied upon to substantiate experimental results, particularly during submission for approval of new molecular entities," commented Neil Kipling, Chairman and CEO of IDBS. "The integration of MathIQ and Vitra's CellCard System moves beyond the current best practice of ad hoc custom integration of assay systems and data analysis software, delivering an off-the-shelf solution with the flexibility to be customized and extended to provide competitive advantage -- with all the advantages of independently validated mathematics and statistics. We are delighted to be working with Vitra to supply this one-of-a-kind data analysis solution."
Vitra's CellCard System provides unique biological insight into the effects of lead compounds upon multiple targets or tissue types by enabling simultaneous analysis of selectivity and activity in a single well. Unlike current serial approaches, single well profiling of compounds allows early assessment of potency, selectivity and mechanism of action of lead compounds. IDBS' MathIQ software complements the CellPlex analysis software by enabling researchers to quickly graph and customize data results with the same sophisticated statistical capabilities found in IDBS' popular XLfit application.
About Vitra Bioscience
Vitra Bioscience, Inc. accelerates the discovery of new medicines by transforming critical rate-limiting steps in lead identification and optimization using its unique CellPlex Assays to deliver multi-dimensional cellular information simultaneously.
Vitra Bioscience's proprietary technology includes advances in cell biology, miniaturization, material science, and state-of-the-art imaging software. Using the proprietary CellCard System, scientists can evaluate potential new drug candidates rapidly and thoroughly, obtaining decision- critical information much earlier in the discovery process. The company is located in Mountain View, California and is backed by Alta Partners, Sofinnova Ventures, Three Arch Partners, Mediphase Venture Partners and Skyline Ventures. For more information about the Company, please visit www.vitrabio.com.
About IDBS
IDBS' vision is to enable and mobilise organisations to work with the best possible information at every stage of the drug creation process. Through a robust software framework providing consistent data capture, integrated discovery processes and accurate correlated predictions, IDBS provides both the environment and the solutions required to shorten the time to market for new drugs.
With integrated and innovative informatics applications, technologies and services, IDBS enables organisations to unlock the value held within their discovery data. IDBS delivers a cohesive method for providing manageable, scalable discovery workflows that can be controlled and shared between organisations and departments, allowing secure, easy access to key data.
Headquartered in Guildford, United Kingdom, IDBS has offices in Emeryville, California; Parsippany, New Jersey; and, Cambridge, Massachusetts. IDBS partners with CTC Laboratory Systems in Japan to market IDBS products and services. Founded in 1989, IDBS employs over 170 people worldwide. For more information, visit: www.idbs.com.
CONTACT: Andrew Whiteley, President & CEO of Vitra Bioscience, +1-650-988-4600, or pr@vitrabio.com;
